ReviewFrontiers in immunology2025
Early events in TCR signaling - the evolving role of ITAMs.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Mapping the TCR landscape: computational tools empowering translational immunology and therapy design.Journal for immunotherapy of cancer · 2026Review
- Engineering a Second Interchain Disulfide Bond in the αβ T-Cell Receptor Constant Domain: A Powerful Strategy to Enhance Stability, Pairing Fidelity, and Therapeutic Efficacy in TCR-T Cell Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Membrane-Based Assembly and Interactions in Immune Receptors.Chemical reviews · 2026Review
- T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy.Journal of cellular and molecular medicine · 2026Review
- Expanding the clinical spectrum of CD3γ deficiency: comprehensive characterization of adult-onset disease and integrated reevaluation of all reported patients.Frontiers in immunology · 2026Review
- Non-Malignant T Cells as Determinants of Immunotherapeutic Response in Chronic Lymphocytic Leukemia: Towards Personalized Strategies.Oncology research · 2026Review
- Low Levels of Mouse γδ T Cell Development Persist in the Presence of Null Mutants of the LAT Adaptor.International journal of molecular sciences · 2025Article
- Unraveling the immune response in optic nerve injury: implications for retinal ganglion cell protection.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The T cell antigen receptor (TCR), a multiprotein complex essential for adaptive immunity, is composed of variable TCRα and TCRβ subunits responsible for antigen recognition and six invariant signal transducing CD3 and ζ subunits. Peptide-MHC (pMHC) binding by TCRα/β dimers results in the transmission of signals mediated by the CD3 and ζ subunits, which each contain one or more immunoreceptor tyrosine-based activation motifs (ITAMs). Several other immune receptors utilize ITAMs for signal transduction; however, while each of these receptors includes between one and three signaling subunits with a single ITAM, the TCR is strikingly unique, containing a total of ten ITAMs distributed within the six CD3 and ζ subunits. Numerous studies conducted over the past twenty-five years have attempted to determine the purpose for the structural singularity of the TCR. From these investigations, three models of ITAM function have emerged: signal discrimination (selective effector binding to different ITAMs), signal amplification (additive effect of ITAMs) and signal duality (activation and inhibition by ITAMs depending on context). In this review, we revisit the long history of ITAM research, which despite intensive investigation, has yet to provide a clear consensus for the role of TCR signaling subunit and ITAM multiplicity. We conclude by relating results from our recent study of the three tandem ζ ITAMs that suggest that at least some TCR ITAMs can transmit both activating (amplifying) and inhibitory signals depending on the affinity of the pMHC-TCR interaction and the subunit context, contributing to and enabling the nuanced regulation of T cell responses by the TCR and helping explain the exquisite ligand discrimination displayed by the TCR. These findings also suggest a model for ligand-mediated antagonism, a well-documented but poorly understood atypical TCR signaling response. Finally, we examine the implications of these findings which provide the basis for a new functional model for TCR ITAM multiplicity. A comprehensive understanding of the roles of ITAMs and the CD3 interactome will emerge from continued investigation, shedding light on the fascinating but still incompletely understood most proximal steps in the TCR signaling cascade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.